Vidofludimus

SKU: orb1305278

Description

Vidofludimus (SC12267) is a potent and selective small molecule inhibitor of dihydroorotate dehydrogenase (DHODH). It has demonstrated efficacy in preclinical models of autoimmune diseases, such as multiple sclerosis and lupus, through both in vitro enzymatic assays and in vivo studies.

Research Area

Cell Biology, Immunology & Inflammation, Metabolism Research, Molecular Biology

Key Properties

• CAS Number: 717824-30-1
• MW: 355.36
• Purity: 99.58% (May vary between batches)
• Formula: C₂₀H₁₈FNO₄
• SMILES: COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1
• Target: Dehydrogenase|||Interleukin|||DNA/RNA Synthesis
• Solubility: H2O:< 1 mg/mL (insoluble or slightly soluble);10% DMSO+90% Corn Oil:3.3 mg/mL (9.29 mM);DMSO:100 mg/mL (281.4 mM);Ethanol:1 mg/mL (2.81 mM)

Bioactivity

• Target IC50:
  DHODH (human):134 nM
• In Vivo:
  In MRLlpr/lpr mice, Vidofludimus (300 mg/kg, p.o.) reduces systemic autoimmunity and improves Lupus Nephritis. In Rats, Vidofludimus (60 mg/kg, p.o.) effectively reduces macroscopic and histological pathology and the numbers of CD3+ T cells. In a rat model of renal transplantation, Vidofludimus (20 mg/kg, p.o.) prolongs survival, paralleled by amelioration of histologic signs of acute rejection.
  Read more...
• In Vitro:
  Vidofludimus causes a concentration dependent inhibition of phytohemagglutinin-stimulated PBMC proliferation via the inhibition of pyrimidine de novo synthesis. Vidofludimus attenuates IL-17 secretion from colonic strips by inhibition of STAT3 and NF-κB activation.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

RNA Synthesis, RNASynthesis, SC 12267, SC12267, SC-12267, Vidofludimus, 4sc-101, DHODH, Dihydroorotate Dehydrogenase, DNASynthesis, DNA/RNA Synthesis, DNA Synthesis, dihydroorotate dehydrogenase (DHODH), Inhibitor, Interleukin Related, Interleukin, farnesoid X receptor (FXR), fatty liver, Human DHODH, FXR, immunomodulatory, inflammatory bowel disease (IBD), NR1H4, inhibit, non-alcoholic fatty liver disease (NAFLD), oral

Compound Identifiers

PubChem CID

9820008